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noAIF 42%AIF). Overall, with each subsequent line of therapy the proportion of AIF
patients taking fulvestrant increased. In addition, of those with AIF, 35% (n905)
switched to chemotherapy prior to study end. CONCLUSIONS: The majority of
ER/HER2-metastatic breast cancer patients treatedwith AIs will fail at least 1 line
of therapy. Prior AI treatment did not appear associated with future AI failure.
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DTIC AND GM-CSF IN THE TREATMENT OF PATIENTS WITH METASTATIC
MELANOMA
Zhao Z, Wang S, Barber B, Wagner V
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OBJECTIVES: To describe patients with metastatic melanoma being treated with
mono-therapy, dacarbazine (DTIC) or granulocyte-macrophage colony-stimulating
factor (GM-CSF). METHODS: Using a large US medical claims database, patients
were identified between 2005 and 2010 using 2 melanoma diagnoses (ICD-9-CM:
172.xx, V10.82) and 2 diagnoses for metastasis (ICD-9-CM: 197.xx, 198.xx). Pa-
tients who received mono-therapy with DTIC or GM-CSF as the first documented
drug therapy after metastatic diagnosis were identified. Patient demographic and
clinical characteristics and treatment duration were compared between patients
treated with DTIC and those who received GM-CSF. Furthermore, comparisons
were also made between the two treatment groups after 1-to-1 matching on age,
gender, and baseline comorbidities. RESULTS: A total of 81 patients with meta-
static melanoma receiving first-line DTIC and 24 patients with metastatic mela-
noma receiving first-line GM-CSF were included in this analysis. On average, DTIC
patients were 8.5 years older (p  0.009) and had higher baseline Charlson Comor-
bidity Index scores (D0.43, p  0.005) than GM-CSF patients. The mean duration of
first line treatment was 94 days on DTIC and 135 days on GM-CSF. Themean length
of follow-up from the start of first line was 257 days on DTIC and 451 days on
GM-CSF. After each GM-CSF patient was matched with a DTIC patient on age,
gender, and baseline Charlson Comorbidity Index score, the mean duration of first
line treatment was 79 days on matched DTIC and 135 days on GM-CSF, and the
mean length of follow-up from the start of first line was 317 days onmatched DTIC
and 451 days on GM-CSF. CONCLUSIONS: Patients withmetastatic melanomawho
received DTIC treatment were older and had higher comorbidity index scores but
shorter treatment duration than those who received GM-CSF; the difference in
treatment duration remained after DTIC patients were matched with GM-CSF pa-
tients on age, gender and comorbidity index scores.
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OBJECTIVES: Lapatinib is an oral dual tyrosine kinase inhibitor that has been
shown to improve time to progression when combined with capecitabine versus
capecitabine monotherapy in women with HER2 MBC previously treated with
trastuzumab. Data on health care utilization and costs among women receiving
lapatinib in typical clinical practice are scarce. METHODS: This was retrospective
observational descriptive study of health care utilization and costs among women
receiving lapatinib after treatment with trastuzumab for MBC in the Thomson
MedStatMarketScan Commercial andMedicare health insurance claims databases
(1/2000-3/2010). Monthly utilization and costs were calculated for the 12 months
prior to initiation of lapatinib (pre-treatment period), the lapatinib treatment pe-
riod, and the post-treatment period (end of lapatinib treatment to end of
study/disenrollment). RESULTS: Mean (SD) age was 52(8) and 72(6) years in Com-
mercial (n572) andMedicare (n94) patients respectively. Lapatinib was initiated
in combination w/capecitabine in 63% and w/trastuzumab in 22% of patients. Me-
dian time to lapatinib discontinuation was 7.4 months. The mean(SD) number of
visits/month declined from 6.1(3.0) during pre-treatment to 5.5(3.5) during treat-
ment, and to 4.6(3.9) during post-treatment. The mean(SD) number of inpatient
days/month increased progressively from 0.24(0.52) during pre-treatment, to
0.53(1.39) during treatment and 0.96(2.52) post-treatment. Mean(SD) lapatinib
costs/month during treatment were $2,097($877). Mean(SD) trastuzumab costs/
month were $2,762($2,020), $722($1,731), and $1,166($2,134) during pre-treatment,
treatment, and post-treatment, respectively. Correspondingmean(SD) chemother-
apy costs/month were $1,355($1,898), $1,496($1,698), and $1,437($2,729), respec-
tively, while corresponding mean(SD) chemotherapy administration costs/month
were $508($477), $189($289), and $326($516) respectively.Mean(SD) other (including
inpatient) costs/month were $5,446($4,680), $5,564($7,198), and $6,880($9,726), re-
spectively. Mean(SD) total costs/month were $10,071($6,056), $10,067($7,695), and
$9,809($10,853), respectively. CONCLUSIONS: In this sample of women receiving
lapatinib after treatment with trastuzumab for MBC, monthly health care costs
were similar during lapatinib treatment versus prior to treatment, despite progres-
sively increasing inpatient utilization and costs, potentially reflecting disease pro-
gression over time.
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OBJECTIVES: Iron deficiency anemia is commonly treated with intravenous (IV)
iron in oncology, especially in combination with erythropoiesis-stimulating
agents. Central venous access port – PortaCath (PAC) – is used to provide long-term
venous access and to deliver chemotherapy in this setting. There is a lack of data,
however, on the use of PAC for the administration of IV iron in cancer patients. The
aim of this survey was to assess the frequency of this practice, and the reasons
supporting it.METHODS: FERPAC was a declarative survey conducted in France. A
total of 497 oncologists/hematologists were interviewed on their practices regard-
ing their use of IV iron. Answers were collected and registered into a central-based
server. RESULTS: A total of 141 questionnaires were collected. Most used IV irons
were iron sucrose and ferric carboxymaltose, for which respectively 77.4% and
77.6% of physicians reported to use the PAC for the administration. The main
reasons for using the PAC were the easy way of administration (28.2%) and the
preservation of patient venous capital (26.1%), given that efficacy and safety were
expected to be at least acceptable or even as good as peripheral administration. IV
iron administration was planned strictly after chemotherapy (45.7%), strictly be-
fore (37.2%), or without any preference (17.0%). Reasons for not using the PACwere
either a history of thrombosis (45.1%) or potential drug-drug interactions (17.7%).
CONCLUSIONS: IV irons are currently commonly administered through the PAC in
cancer patients in France. Further studies are needed to confirm the efficacy and
safety of the administration of IV iron through PAC.
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OBJECTIVES: To determine the utilization and predictors of Cyclophosphamide-
Methotrexate-Fluorouracil (CMF) chemotherapy in women with early stage breast
cancer.METHODS:A longitudinal studywas conducted including patients 66 years
and above, diagnosed with stage I-III breast cancer using SEER cancer registry data
linkedwithMedicare claims. Patientswere divided into two groups as those receiv-
ing CMF chemotherapy and those receiving other chemotherapy. A patient was
considered as receiving CMF chemotherapy if she started chemotherapywithin six
months and had a claim of Cyclophosphamide, Methotrexate and 5-Fluorouracil
within one year of diagnosis. Multiple logistic regression was conducted to assess
the predictors of CMF chemotherapy use. RESULTS: A total of 11,322 women re-
ceived chemotherapy within the first six months and 24.4% of these (n  2758)
received CMF chemotherapy. A patient had 2.3 times greater odds of receiving CMF
chemotherapy with each year increase in age. Patients who received a lymph node
dissection had 1.4 times greater odds of receiving CMF chemotherapy than patients
who did not receive it. Patients with stage II tumor had 1.5 times greater odds of
receiving CMF chemotherapy than stage I patients. CMF use decreased by 23%with
estrogen receptor positivity and 18% when radiation was administered to the pa-
tient. Patients with Charlson’s comorbidity index  1 were 16% more likely to
receive CMF chemotherapy than patients who had a Charlson’s comorbidity score
of 0. CMF use decreased overall with time. CONCLUSIONS: This study found that
age, comorbidity index, estrogen receptor status, radiation and lymph node dissec-
tion were significant predictors of CMF chemotherapy. The use of CMF chemother-
apy increased with age, comorbidity index and lymph node dissection and de-
creased with estrogen receptor positivity and irradiation. The declining time trend
in the use of CMF chemotherapy probably indicates the increased use of newer
chemotherapy regimens like the Anthracycline and Taxane based regimens.
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OBJECTIVES: Evidences-based literature has confirmed the effectiveness of radia-
tion therapy (RT) following breast conserving surgery (BCS); thus several practice
guidelines recommend RT after BCS. This study explored factors associated guide-
line compliance among young women with insurance because compliance in this
population is not well-understood. METHODS: Using the 2004-2009 MarketScan®
Research Database, we identified our study cohort as women who had a BCS be-
tween July 1, 2004 and December 31, 2008, and had continuous enrollment from 6
months before to 12 months after the date of BCS. We excluded patients who had
mastectomy within 3 months of BCS. We used Pearson Chi-Squared test and mul-
tivariate logistic regression to ascertain factors associated the receipt of RT within
one year of BCS. We performed Hosmer-Lemeshow goodness-of-fit and other
model diagnostic tests to determine the finalmodel specification and conducted all
analyses using SAS® 9.2 and Stata® 11.0 software. RESULTS: A total of 20,756 of the
24,011 (86.44%) BCS patients received RTwithin a year of their surgery. Results from
the logistic regression showed that the odds of RT increased with age, compared
with patients under 40, the odds ratio was 1.63 (95% confidence interval: 1.40-1.90),
1.86 (1.61-2.16), and 2.04 (1.73-2.39) for those in 40-49, 50-59, and  60 age group,
respectively. Patients who did not enroll in HMOs (1.27; 1.17-1.37) and was primary
insurance policy holder (1.31; 1.21-1.41)were significantlymore likely to receive RT.
Comparewith patients resided in the Northeast region, those in theWest were less
likely to receive RT (0.71; 0.62-0.82). Positive association with hospital density was
also observed (1.17; 1.04-1.31). CONCLUSIONS: Although the compliance rate
among young women with employment-based insurance was higher than that
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reported among the elderly (74.21%), significant variations across age groups, re-
gions, and insurance types observed in this well-insured group call for future re-
search to better understand reasons behind these variations.
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OBJECTIVES: In Japan, the screening rates for breast and cervical cancers have been
lower than in other countries, with rates below 20%. Breast cancer screening has
been conducted biennially for over 40 years, and cervical cancer screening has been
conducted biennially for over 20 years. Since lack of resources is an important
barrier to increasing cancer screening rates, relationships between resources and
cancer screening rates were investigated for breast and cervical cancers in Japan.
METHODS: Based on the national data from 2008, the resource gap among 47
prefectures was compared. Resources were defined by the number of mammogra-
phy equipment installations (per 100,000 women) for breast cancer screening and
the number of gynecologists (per 100,000 women) for cervical cancer screening.
Correlations between the screening rates and the availability of resources were
calculated. RESULTS: The national average breast cancer screening rate was 14.7%,
varying from 2.5% to 35% among the 47 prefectures. The national average number
of mammography equipment installations was 5.88 per 100,000, ranging from 8.81
to 4.41 per 100,000 among the 47 prefectures. The correlation between mammog-
raphy equipment installations and the screening rate for breast cancer was 0.420
(P0.01). The national average cervical cancer screening rate was 19.4%, varying
from 12.1% to 34.8% among the 47 prefectures. The national average number of
gynecologists was 18.0 per 100,000, ranging from 13.1 to 25.9 per 100,000 among the
47 prefectures. The correlation between the number of gynecologists and the cer-
vical cancer screening rate was -0.079 (n.s). CONCLUSIONS: Although the breast
cancer screening rate shows a close relationshipwithmedical resource availability,
there is no relationship for cervical cancer screening. Since medical resources to
increase breast cancer screening are limited in local areas, sufficient resources
should be provided. In cervical cancer screening, other factors that affect the
screening rate should be investigated.
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OBJECTIVES: Non-participation by potential study subjects in population research
can affect the validity and generalizability of study outcomes. The study objectives
were to evaluate the differences between participants and non-participants who
were targeted for enrollment in the Bonnie’s Bus Mobile Mammography Program
(BBMMP) conducted throughout West Virginia, and to determine the predictors of
willingness to participate in future research among those who consented to pro-
vide initial surveillance data. METHODS: Data collected from 2441 women who
were screened in the BBMMP were analyzed using the chi-square test and logistic
regression. RESULTS: Of the 2441 women who were screened by BBMMP over a 3
year period, 1178 women (48.3%) chose not to consent to participate in the surveil-
lance study. Bivariate analysis indicated that being over 65 years, single, over-
weight, uninsured, unemployed, or of minority race were associated with non-
enrollment in the study. The multivariate adjusted model indicated that being of
age 65 years and above (AOR2.10), being single (AOR1.25), or being from a mi-
nority race (AOR1.97) were significant predictors of non-participation. Of the
1,263 women who consented to participate in the study and provided surveillance
data, 407 women (32.2%) declined to being contacted for participation in future
breast cancer screening research. The unadjustedmodel showed that womenwho
have breast problems, are adherent to mammography screening guidelines, and
aremarried/partnered aremore likely to bewilling to participate in future research.
Multivariate logistic regression analysis revealed that women adherent to mam-
mography screening guidelines are more likely to agree (AOR1.40) to participate
in future research than non adherent women. CONCLUSIONS:Women who are at
risk for breast cancer and who are likely targets for interventions to increase ad-
herence to mammography screening guidelines are more likely to not participate
in breast cancer screening studies than those who may not be at risk and are
adherent to screening guidelines.
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OBJECTIVES: Few studies have focused on access to care for women through utili-
zation of a mobile mammography unit. Bonnie’s Bus Mammography Mobile Pro-
gram (BBMMP) was created to provide mammograms to women in rural areas
throughout West Virginia (WV) and surrounding areas. Based on a 3-year analysis
of the data, 80.4% of its clientele had a BMI of 30 or above as compared to 64.9% for
all WV women age 40 and above. Thus, the objectives of the study were to: 1) to
describe the demographics and comorbidities of womenwho utilized BBMP, and 2)
to determine the association between BMI and personal health and screening his-
tory, preventive care, and wellness behaviors. METHODS: Three years BBMP sur-
veillance data collected from 1099 women age 40 and above were analyzed. BMI by
personal health and screening history, preventive care, wellness behaviors, and
demographics were analyzed using descriptive statistics, chi-square tests, and a
linear regression model. RESULTS: Women were mostly married (60.4%), had
health insurance (53.2%), were employed (46.5%), and had an annual income be-
tween $10,000-25,000 (40.9%). Major comorbidities were hypertension (49%) and
high cholesterol (43.9%). Increasing BMI was associated with greater likelihood of
thyroid disease, hypertension, diabetes, high cholesterol, allergies, hormone re-
placement therapy use, activity limitations, perceived weight problem, lower ex-
ercise, inability to getmedications due to cost, lower doctor visits, and being single.
Those with lower BMI were less likely to smoke or drink alcohol. The regression
model was significant (F13.729, p0.001, R2  0.412) and indicated that women
who engaged in preventive care behaviors were less likely to be obese than those
who did not. CONCLUSIONS: The BBMMP attracted women who were dispropor-
tionately obese and had multiple co-morbidities, thus providing a great opportu-
nity for targeted interventions related to improving preventive care, screening, and
self-care behaviors.
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OBJECTIVES: Specialty pharmacy programs are increasingly used to improve the
quality of outpatient therapy with oral medications for cancer. We evaluated
whether use of particular specialty pharmacy services is associated with improved
oncology medication use and reduced overall healthcare costs, as compared to
retail pharmacy services. METHODS: The study is a retrospective claims analysis
post implementation of a specialty pharmacy program, by a national commercial
payer. A matched sample of patients assigned to use specialty pharmacies and
those who used retail pharmacies for oral cancer therapies were compared. Pri-
mary outcomes were financial, including overall health care costs, outpatient
costs, medical costs, and pharmacy costs. Outcomes one year post-implementa-
tion in specialty pharmacy users and retail pharmacy controlswere comparedwith
t-tests for continuous variables, chi-square for nominal variables, and logistic re-
gression for matching. Propensity scores were used to adjust for unmeasured con-
founding in the groups. RESULTS: The final analysis included 464 patients per
cohort. The mean total costs per patient was 13% lower in the specialty pharmacy
group ($84,105 vs. $97,196; difference  $-13,092; P  0.02) in the follow-up period.
The mean outpatient hospital costs ($16,777 vs. $28,629, difference  $-11,852; P 
0.01) were lower in the specialty group by 41%, with an associated significant dif-
ference in outpatient hospital visits (15.75 vs. 19.66, P  0.01). Patients in the spe-
cialty pharmacy groupweremore adherent to therapy, MPR 0.73 vs. 0.66, (P 0.01).
CONCLUSIONS: This specialty pharmacy program implemented by a national
commercial payer appears to improve oral oncology medication adherence and
decrease overall health care costs, mainly by impacting outpatient hospital utili-
zation.
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OBJECTIVES: The rising costs of cancer care have caused concerns regarding the
increasingOOP burden on cancer patients. The objective of this study is to examine
patients’ OOP expenditures on G-CSF, pegfilgrastim and filgrastim, two supportive-
care agents for cancer patients treated with myelosuppressive chemotherapy.
METHODS: Two large US health care claims databases (2008-Q2 2010 MarketScan®
Commercial and Medicare Supplemental Databases, and 2007-Q2 2009 HealthCore
Integrated Research DatabaseSM) were used to identify adult patients receiving
chemotherapy and G-CSF in outpatient settings. The summary statistics of quar-
terly OOP costs were tabulated for patients with any G-CSF claim for each quarter
during Q1 2007-Q2 2010. Costs were adjusted to June 2010 dollars. RESULTS: The
pattern of patients’ OOP costs for G-CSF was generally consistent between the two
data sources and over time. On average, about 65-75% of patients on G-CSF in-
curred zero OOP costs in a quarter. Across the years, the average quarterly OOP
costs per patient for all patients ranged from $100-$150 for pegfilgrastim and $50-
$100 for filgrastim.When focusing on the 20,948 patients onG-CSFwith continuous
health plan enrollment throughout 2009 in MarketScan®, mean OOP costs/patient/
quarter were $100 for pegfilgrastim and $53 for filgrastim. On average 69.2% of
pegfilgrastim patients and 63.9% of filgrastim patients had zero OOP costs in a
quarter. Very few patients (5.5% of pegfilgrastim and 2.7% of filgrastim) had quar-
terly OOP costs reaching $500 or above. The subgroup of patients with $0 quar-
terly OOP costs had mean costs/patient/quarter that were $324 for pegfilgrastim
and $146 for filgrastim. During 2009, that subgroup had an average of 2.4 adminis-
trations and/or prescriptions per quarter for pegfilgrastim and 5.5 for filgrastim.
The mean OOP costs of those administrations and/or prescriptions were $128 for
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